West John Stephen

About West John Stephen

John West is a veteran life-sciences executive best known for his role as co-founder and former Chief Executive Officer of Personalis, Inc. He co-founded Personalis in 2011 with Stanford faculty members, building the company around the growing opportunity in precision oncology and large-scale genomic analysis. At Personalis, he served as CEO and was also a member of the board of directors until he stepped down from the role at the end of 2022. After leaving the CEO position, he continued as an advisor to the Board, which suggests that his strategic perspective remained valued by the company. ([investors.personalis.com](https://investors.personalis.com/news-releases/news-release-details/personalis-announces-ceo-retirement-and-transition/?utm_source=openai)) Before Personalis, West developed a long career in DNA sequencing and genomics commercialization. Public sources show that he served as Chief Executive Officer of Solexa, a sequencing-technology company, and later joined Illumina following Illumina’s acquisition of Solexa, where he became Senior Vice President of DNA Sequencing. A corporate biography also notes earlier executive responsibility at Applied Biosystems. Taken together, these roles point to a career focused on bringing next-generation sequencing technologies from development into commercial scale. ([sec.gov](https://www.sec.gov/Archives/edgar/data/913275/000095012306014140/y27170fe425.htm?utm_source=openai)) At Personalis, West’s most notable contribution was helping guide the company’s scientific and commercial direction in advanced cancer genomics. Company communications cite him in connection with product strategy, platform launches, and the broader mission of enabling more comprehensive tumor and immune-system characterization. His leadership profile reflects deep expertise in sequencing technology, operational execution, and the translation of genomic data into clinical and research applications. ([investors.personalis.com](https://investors.personalis.com/news-releases/news-release-details/personalis-inc-launches-immunoid-next-first-platform-providing?utm_source=openai)) From a corporate-governance perspective, West stands out as a founder-operator who has helped shape several important phases in the genomics industry: the growth of Solexa, the scale-up of sequencing at Illumina, and the strategic build-out of Personalis. For U.S. public-market audiences, he represents a classic life-sciences executive profile combining technical depth, company-building experience, and board-level oversight. ([investors.personalis.com](https://investors.personalis.com/news-releases/news-release-details/personalis-announces-ceo-retirement-and-transition/?utm_source=openai))